Common human cancers have been found to be frequently associated with somatic mutations in dominant and recessive oncogenes including the p53 gene, and often produce mutant oncogene proteins that are uniquely present in the patient's cancer but not in his/her normal cells. These tumor-specific proteins could form the basis for highly tumor-specific cellular immunotherapy which targets an epitope that is present in each cancer cell and is fundamental to the maintenance of the malignant phenotype. It is now known that cytotoxic T lymphocytes (CTL) detect target cells for killing by recognizing short peptide fragments of endogenous proteins which are presented to them by class I MHC molecules on the surface of the target cell. The target proteins therefore do not have to be normally expressed on the cell surface. The applicant has developed effective methods for induction of mutant oncogene-specific CTL in animals, and has detected such responses in humans and shown that he can induce them in animals and humans with peptide vaccination. The applicant also has evidence that progressively advanced stages of breast cancer are associated with defects in antigen presentation, and specifically poor dendritic cell (DC) function, associated with defects in maturation from stem cells. The applicant has discovered that this at least is partly mediated by tumor-derived VEGF production.
The specific aims of this application are: 1) continue to assess the frequency and clinical significance of anti-p53 CTL in patients with breast cancer, 2) determine the frequency and clinical significant of DC dysfunction and its relation to the development of anti-p53 CTL, and 3) characterize dendritic cells genetically engineered to express T-cell epitopes as an alternative to peptide pulsing for autologous cell vaccines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA061242-04
Application #
2008328
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1994-06-01
Project End
2000-05-31
Budget Start
1997-07-25
Budget End
1998-06-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Carbone, David P; Ciernik, I Frank; Kelley, Michael J et al. (2005) Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23:5099-107
Almand, B; Resser, J R; Lindman, B et al. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755-66
Ishida, T; Chada, S; Stipanov, M et al. (1999) Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 117:244-51
Ciernik, I F; Romero, P; Berzofsky, J A et al. (1999) Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. Int J Radiat Oncol Biol Phys 45:735-41
Oyama, T; Ran, S; Ishida, T et al. (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 160:1224-32
Gabrilovich, D I; Corak, J; Ciernik, I F et al. (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3:483-90
Ciernik, I F; Berzofsky, J A; Carbone, D P (1996) Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope and are lysed by mutant-specific cytotoxic T lymphocytes. Clin Cancer Res 2:877-82
Gabrilovich, D I; Ciernik, I F; Carbone, D P (1996) Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 170:101-10
Gabrilovich, D I; Chen, H L; Girgis, K R et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096-103